Parechovirus A Infections in Healthy Australian Children During the First 2 Years of Life: A Community-based Longitudinal Birth Cohort Study.
clinical epidemiology
healthy children
longitudinal study
parechovirus
viral infection
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
24 06 2020
24 06 2020
Historique:
received:
14
04
2019
accepted:
07
08
2019
pubmed:
14
8
2019
medline:
13
3
2021
entrez:
14
8
2019
Statut:
ppublish
Résumé
Hospital-based studies identify parechovirus (PeV), primarily PeV-A3, as an important cause of severe infections in young children. However, few community-based studies have been published and the true PeV infection burden is unknown. We investigated PeV epidemiology in healthy children participating in a community-based, longitudinal birth cohort study. Australian children (n = 158) enrolled in the Observational Research in Childhood Infectious Diseases (ORChID) study were followed from birth until their second birthday. Weekly stool and nasal swabs and daily symptom diaries were collected. Swabs were tested for PeV by reverse-transcription polymerase chain reaction and genotypes determined by subgenomic sequencing. Incidence rate, infection characteristics, clinical associations, and virus codetections were investigated. PeV was detected in 1423 of 11 124 (12.8%) and 17 of 8100 (0.2%) stool and nasal swabs, respectively. Major genotypes among the 306 infection episodes identified were PeV-A1 (47.9%), PeV-A6 (20.1%), and PeV-A3 (18.3%). The incidence rate was 144 episodes (95% confidence interval, 128-160) per 100 child-years. First infections appeared at a median age of 8 (interquartile range, 6.0-11.7) months. Annual seasonal peaks changing from PeV-A1 to PeV-A3 were observed. Infection was positively associated with age ≥6 months, summer season, nonexclusive breastfeeding at age <3 months, and formal childcare attendance before age 12 months. Sole PeV infections were either asymptomatic (38.4%) or mild (32.7%), while codetection with other viruses in stool swabs was common (64.4%). In contrast with hospital-based studies, this study showed that diverse and dynamically changing PeV genotypes circulate in the community causing mild or subclinical infections in children.Parechovirus can cause severe illnesses in children. However, studies focus mainly on hospitalized populations. True disease burden in the community remains largely unknown. From our community-based cohort, we found diverse parechovirus genotypes in the community, causing mild or subclinical infections in children. NCT01304914.
Sections du résumé
BACKGROUND
Hospital-based studies identify parechovirus (PeV), primarily PeV-A3, as an important cause of severe infections in young children. However, few community-based studies have been published and the true PeV infection burden is unknown. We investigated PeV epidemiology in healthy children participating in a community-based, longitudinal birth cohort study.
METHODS
Australian children (n = 158) enrolled in the Observational Research in Childhood Infectious Diseases (ORChID) study were followed from birth until their second birthday. Weekly stool and nasal swabs and daily symptom diaries were collected. Swabs were tested for PeV by reverse-transcription polymerase chain reaction and genotypes determined by subgenomic sequencing. Incidence rate, infection characteristics, clinical associations, and virus codetections were investigated.
RESULTS
PeV was detected in 1423 of 11 124 (12.8%) and 17 of 8100 (0.2%) stool and nasal swabs, respectively. Major genotypes among the 306 infection episodes identified were PeV-A1 (47.9%), PeV-A6 (20.1%), and PeV-A3 (18.3%). The incidence rate was 144 episodes (95% confidence interval, 128-160) per 100 child-years. First infections appeared at a median age of 8 (interquartile range, 6.0-11.7) months. Annual seasonal peaks changing from PeV-A1 to PeV-A3 were observed. Infection was positively associated with age ≥6 months, summer season, nonexclusive breastfeeding at age <3 months, and formal childcare attendance before age 12 months. Sole PeV infections were either asymptomatic (38.4%) or mild (32.7%), while codetection with other viruses in stool swabs was common (64.4%).
CONCLUSIONS
In contrast with hospital-based studies, this study showed that diverse and dynamically changing PeV genotypes circulate in the community causing mild or subclinical infections in children.Parechovirus can cause severe illnesses in children. However, studies focus mainly on hospitalized populations. True disease burden in the community remains largely unknown. From our community-based cohort, we found diverse parechovirus genotypes in the community, causing mild or subclinical infections in children.
CLINICAL TRIALS REGISTRATION
NCT01304914.
Identifiants
pubmed: 31406985
pii: 5549073
doi: 10.1093/cid/ciz761
pmc: PMC7108192
doi:
Banques de données
ClinicalTrials.gov
['NCT01304914']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
116-127Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Clin Microbiol Rev. 2017 Nov 15;31(1):
pubmed: 29142080
J Clin Virol. 2008 Feb;41(2):69-74
pubmed: 18354819
Thorax. 2018 Oct;73(10):969-979
pubmed: 29247051
J Infect Dis. 2009 Jun 15;199(12):1753-60
pubmed: 19456229
J Clin Virol. 2018 Jan;98:28-32
pubmed: 29223126
J Clin Virol. 2012 Jun;54(2):156-61
pubmed: 22406272
Clin Infect Dis. 2018 Apr 17;66(9):1411-1418
pubmed: 29149283
J Clin Virol. 2015 Sep;70:105-108
pubmed: 26305831
Sci Rep. 2017 Jun 20;7(1):3861
pubmed: 28634337
J Clin Virol. 2015 Oct;71:40-3
pubmed: 26370313
J Clin Microbiol. 2008 Dec;46(12):3965-70
pubmed: 18945833
J Clin Virol. 2015 Mar;64:59-63
pubmed: 25728080
J Paediatr Child Health. 2018 Mar;54(3):289-295
pubmed: 28960646
Emerg Infect Dis. 2019 Jan;25(1):148-152
pubmed: 30561318
Emerg Infect Dis. 2015 Jul;21(7):1144-52
pubmed: 26082289
Pediatr Pulmonol. 2016 Dec;51(12):1336-1346
pubmed: 27228308
J Pediatric Infect Dis Soc. 2018 May 15;7(2):104-112
pubmed: 28369502
Lancet Infect Dis. 2019 Feb;19(2):e51-e58
pubmed: 30322791
J Pediatric Infect Dis Soc. 2019 Dec 27;8(6):501-506
pubmed: 30184210
Am J Epidemiol. 2016 Apr 1;183(7):664-70
pubmed: 26968944
Pediatr Infect Dis J. 2019 Jan;38(1):1-5
pubmed: 30204658
J Clin Microbiol. 2012 Dec;50(12):4111-3
pubmed: 23015672
Microbiol Immunol. 2016 Dec;60(12):854-858
pubmed: 27925289
J Med Virol. 2008 Oct;80(10):1835-42
pubmed: 18712841
PLoS One. 2016 Jul 19;11(7):e0159196
pubmed: 27433803
Pediatr Infect Dis J. 2018 Dec;37(12):1304-1308
pubmed: 30382954
J Clin Virol. 2014 Jun;60(2):84-9
pubmed: 24690382
Epidemiol Infect. 2016 Dec;144(16):3451-3460
pubmed: 27571735
J Clin Microbiol. 2008 Oct;46(10):3446-53
pubmed: 18753351
Arch Dis Child. 2018 Nov;103(11):1061-1066
pubmed: 29871901
J Clin Virol. 2013 Sep;58(1):211-5
pubmed: 23891146
Pediatr Diabetes. 2011 Feb;12(1):58-62
pubmed: 21226816
BMJ Open. 2012 Oct 31;2(6):
pubmed: 23117571
J Clin Microbiol. 2010 Jan;48(1):115-9
pubmed: 19864477